A detailed history of Fred Alger Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fred Alger Management, LLC holds 60,203 shares of VRTX stock, worth $27.9 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
60,203
Previous 59,328 1.47%
Holding current value
$27.9 Million
Previous $24.8 Million 13.79%
% of portfolio
0.14%
Previous 0.13%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $343,708 - $424,838
875 Added 1.47%
60,203 $28.2 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $62.9 Million - $68.8 Million
-154,179 Reduced 72.21%
59,328 $24.8 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $1.25 Million - $1.5 Million
-3,646 Reduced 1.68%
213,507 $86.9 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $4.9 Million - $5.25 Million
14,476 Added 7.14%
217,153 $75.5 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $10.2 Million - $11.4 Million
32,509 Added 19.1%
202,677 $71.3 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $66.5 Million - $75.8 Million
-234,697 Reduced 57.97%
170,168 $53.6 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $35.1 Million - $39.5 Million
-122,841 Reduced 23.28%
404,865 $117 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $8.04 Million - $8.97 Million
29,367 Added 5.89%
527,706 $153 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $15.5 Million - $19.3 Million
65,885 Added 15.24%
498,339 $140 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $9.5 Million - $11.2 Million
42,908 Added 11.01%
432,454 $113 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $68.5 Million - $86.4 Million
386,859 Added 14397.43%
389,546 $85.5 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $21,585 - $24,155
-119 Reduced 4.24%
2,687 $487,000
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $35 Million - $41.3 Million
-186,780 Reduced 98.52%
2,806 $566,000
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $77.5 Million - $90.4 Million
-374,511 Reduced 66.39%
189,586 $40.7 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $103 Million - $137 Million
-496,000 Reduced 46.79%
564,097 $133 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $13.9 Million - $16.5 Million
-54,485 Reduced 4.89%
1,060,097 $288 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $119 Million - $156 Million
-525,995 Reduced 32.06%
1,114,582 $324 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $4.38 Million - $5.44 Million
21,934 Added 1.36%
1,640,577 $390 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $30.9 Million - $41.4 Million
185,055 Added 12.91%
1,618,643 $354 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $16.5 Million - $18.5 Million
99,046 Added 7.42%
1,433,588 $243 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $5.63 Million - $6.51 Million
-34,213 Reduced 2.5%
1,334,542 $245 Million
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $102 Million - $121 Million
-621,959 Reduced 31.24%
1,368,755 $252 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $609,614 - $771,338
4,013 Added 0.2%
1,990,714 $330 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $4.4 Million - $5.05 Million
26,208 Added 1.34%
1,986,701 $383 Million
Q2 2018

Jul 19, 2018

BUY
$145.72 - $169.96 $27.8 Million - $32.5 Million
191,072 Added 10.8%
1,960,493 $333 Million
Q1 2018

May 10, 2018

SELL
$151.6 - $177.13 $37.8 Million - $44.2 Million
-249,477 Reduced 12.36%
1,769,421 $288 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $40.3 Million - $45.6 Million
293,215 Added 16.99%
2,018,898 $303 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $256 Million - $280 Million
1,725,683
1,725,683 $262 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.